Chemically amplified photoresist as a medium for quantitative 3-D high spatial resolution autoradiography
暂无分享,去创建一个
Sverre Myhra | Bart Cornelissen | Katherine A. Vallis | Nadia Falzone | B. Cornelissen | S. Myhra | K. Vallis | R. Nathan | N. Falzone | Roger Nathan | Radka Chakalova | Thomas Altebaeumer | R. Chakalova | T. Altebaeumer
[1] J. Mazziotta,et al. Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .
[2] Claude Comtat,et al. Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.
[3] Christer Halldin,et al. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[4] B. Gulyás,et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE‐PE2I, a new dopamine transporter PET radioligand , 2009, Synapse.
[5] Ronald Boellaard,et al. Optimization algorithms and weighting factors for analysis of dynamic PET studies , 2006, Physics in medicine and biology.
[6] Christine DeLorenzo,et al. Modeling Considerations for In Vivo Quantification of the Dopamine Transporter using [11C]PE2I and Positron Emission Tomography , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] J. Seidel,et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Christer Halldin,et al. Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] Christer Halldin,et al. Radioligand Disposition and Metabolism — Key Information in Early Drug Development , 1995 .
[10] Robert B. Innis,et al. Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors , 1999 .
[11] J. Seibyl,et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] C. Halldin,et al. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. , 2009, Bioorganic & medicinal chemistry letters.
[13] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[14] G. Gebhart,et al. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. , 1997, ILAR journal.
[15] Christer Halldin,et al. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Yuan-Hwa Chou,et al. [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[17] N. Logothetis,et al. A combined MRI and histology atlas of the rhesus monkey brain in stereotaxic coordinates , 2007 .
[18] Christer Halldin,et al. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor , 2005, Psychopharmacology.
[19] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] D. Comar,et al. PET for drug development and evaluation , 1995 .
[21] D. Lewis,et al. Tyrosine Hydroxylase- and Dopamine Transporter-Immunoreactive Axons in the Primate Cerebellum , 2000, Neuropsychopharmacology.